Stories from people navigating Multiple Myeloma — diagnosis, treatment, caregiving, and the ordinary days in between.
4 stories
Oncology
The accelerated approval covers eligible adults with previously treated multiple myeloma after exposure to both a proteasome inhibitor and an immunomodulatory agent.
Rayan Salih · August 31, 2026 · 6 min
Oncology
In ENDURANCE, indefinite lenalidomide maintenance did not improve 7-year overall survival versus a fixed 2-year course for standard-risk myeloma managed without upfront transplant.
Rayan Salih · 6 min read
Oncology
The newest class of myeloma immunotherapies target a surface protein called GPRC5D.
Rayan Salih · 10 min read
Oncology
The US Food and Drug Administration (FDA) has approved a new combination treatment for patients with relapsed/refractory multiple
Rayan Salih · 9 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.